Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Depression
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions: Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Major Depressive Disorder
Interventions: Transcranial Photobiomodulator, Sham; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Orangeburg, New York

Conditions: Major Depressive Episode
Interventions: Medibio Depression Diagnostic Aid, Mini International Neuropsychiatric Interview, Hamilton Rating Scale for Depression - 17 Item; Diagnostic Test
Lead sponsor: Medibio Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Garden Grove, California • Torrance, California • Mason, Ohio + 3 more

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 3
States / cities: Irvine, California • Stanford, California • New York, New York

Conditions: Major Depression
Interventions: High intensity whole-body infrared heating, Low intensity whole-body infrared heating, Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG), Questionnaires; Device · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 30 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Schizo Affective Disorder
Interventions: FOCUS participants; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: St Louis, Missouri • Dover, New Hampshire • Manchester, New Hampshire

Conditions: Depressive Disorder, Major
Interventions: PCIT-ED; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 36 Months to 83 Months
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depressive Disorder
Interventions: AGN-241751, Placebo; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • Garden Grove, California • Atlanta, Georgia + 2 more

Conditions: Major Depressive Disorder
Interventions: pharmacogenetic testing; Other
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Major Depressive Disorder
Interventions: Duloxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 9
States / cities: Trumbull, Connecticut • Lafayette, Indiana • Gaithersburg, Maryland + 6 more

Conditions: Psychosocial Functioning, Stress Disorders, Post-Traumatic, Depressive Disorder, Major
Interventions: Self-Guided STAIR Coach with Real-Time Assessment, Real-Time Assessment; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Major Depressive Disorder (MDD)
Interventions: CTC-501; Drug
Lead sponsor: Chase Therapeutics Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Major Depressive Disorder
Interventions: Stimulation-ON, Stimulation-OFF, Stimulation-ON Active Control; Device
Lead sponsor: Andrew Krystal; Other
Eligibility: 22 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2035
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Depression, Major Depressive Disorder
Interventions: MoodTriggers Application; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Hanover, New Hampshire • Lebanon, New Hampshire

Conditions: Anorexia Nervosa, Major Depressive Disorder, Generalized Anxiety Disorder, Panic Disorder, Brain Injury
Interventions: Isoproterenol, Normal saline; Drug
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Major Depressive Disorder
Interventions: Lipopolysaccharide, Placebo; Biological
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Major Depressive Disorder, Breast Cancer, Venlafaxine
Interventions: Interpersonal Psychotherapy, Venlafaxine HCl ER; Behavioral · Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 46
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more

Conditions: Major Depressive Disorder Without Psychotic Features
Interventions: Asenapine 5-20 mg daily, Placebo 1-4 tablets daily; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina + 1 more

Conditions: Major Depressive Disorder
Interventions: Left DLPFC tDCS, Right DLPFC tDCS, Cognitive task; Device · Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 20 Years to 55 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Major Depression
Interventions: Guideline-Based Medical Management, Motivational Interviewing for Depression; Behavioral
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Major Depression
Interventions: Psilocybin, modafinil, zolpidem, pimavanserin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Minneapolis, Minnesota + 1 more

Search by objective public record fields.

Examining the Link Between Depression and Seasonal Allergies

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33

Medibio DDA Confirmatory Performance Study

Identifying Biological Markers for Severe Depression

The Brain on Whole Body Hyperthermia: A Neuroimaging Study

Technology-Assisted Implementation of a Mobile Health Program for Serious Mental Illness

A Randomized Controlled Trial of PCIT-ED for Preschool Depression

Zelquistinel in the Treatment of Adults With Major Depressive Disorder

Pharmacogenetic Testing on an Outpatient Population With a Depression Diagnosis

Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression

A Mobile Health Intervention to Improve Psychosocial Functioning in Veterans With Posttraumatic Stress Disorder and Depression Symptoms

A Study in Patients With Major Depressive Disorder

Closed-Loop Deep Brain Stimulation for Major Depression

Remote Evaluation and Alerting for Collaborative Health (REACH) in Depression

Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa

Lipopolysaccharide (LPS) Challenge in Depression

Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression

Evaluating tDCS Brain-stimulation in Depression Using MRI

Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder

Motivational Interviews for Depression in Primary Care

Psilocybin for Depression in Veterans